Novavax/$NVAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novavax
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Ticker
$NVAX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
952
ISIN
US6700024010
Website
Novavax Metrics
BasicAdvanced
$1.1B
2.39
$2.97
3.21
-
Price and volume
Market cap
$1.1B
Beta
3.21
52-week high
$17.81
52-week low
$5.01
Average daily volume
5.5M
Financial strength
Current ratio
2.056
Quick ratio
1.783
Long term debt to equity
-295.045
Total debt to equity
-302.287
Interest coverage (TTM)
19.68%
Profitability
EBITDA (TTM)
467.502
Gross margin (TTM)
58.50%
Net profit margin (TTM)
38.18%
Operating margin (TTM)
33.69%
Effective tax rate (TTM)
2.06%
Revenue per employee (TTM)
$1,320,000
Management effectiveness
Return on assets (TTM)
20.27%
Return on equity (TTM)
-101.56%
Valuation
Price to earnings (TTM)
2.387
Price to revenue (TTM)
0.891
Price to book
-15.2
Price to tangible book (TTM)
-6.13
Price to free cash flow (TTM)
-5.641
Free cash flow yield (TTM)
-17.73%
Free cash flow per share (TTM)
-125.86%
Growth
Revenue change (TTM)
25.91%
Earnings per share change (TTM)
-185.20%
3-year revenue growth (CAGR)
-3.65%
10-year revenue growth (CAGR)
43.85%
3-year earnings per share growth (CAGR)
-44.62%
10-year earnings per share growth (CAGR)
-9.41%
What the Analysts think about Novavax
Analyst ratings (Buy, Hold, Sell) for Novavax stock.
Bulls say / Bears say
Novavax's recent partnership with Sanofi, valued at $1.2 billion, enhances its distribution capabilities and provides significant financial support for ongoing vaccine development. (reuters.com)
The FDA's full approval of Novavax's COVID-19 vaccine, Nuvaxovid, for individuals aged 65 and older, marks a significant regulatory milestone, potentially boosting market confidence and sales. (reuters.com)
Novavax reported a substantial revenue increase to $667 million in Q1 2025, driven by the recognition of $603 million from the termination of agreements with Canada and New Zealand, indicating improved financial health. (reuters.com)
Novavax reduced its 2024 revenue forecast due to anticipated lower sales of its COVID-19 vaccine, reflecting challenges in market penetration and competition. (reuters.com)
The company faces ongoing discussions with the FDA regarding post-marketing commitments for its COVID-19 vaccine, which could delay broader market access and require additional resources. (reuters.com)
Novavax's stock price has decreased by approximately 47.57% over the past 52 weeks, indicating potential investor concerns about the company's long-term growth prospects. (stockanalysis.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Novavax Financial Performance
Revenues and expenses
Novavax Earnings Performance
Company profitability
Novavax News
AllArticlesVideos
Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study
Reuters·4 weeks ago
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Reuters·1 month ago
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.
Barrons·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novavax stock?
Novavax (NVAX) has a market cap of $1.1B as of July 11, 2025.
What is the P/E ratio for Novavax stock?
The price to earnings (P/E) ratio for Novavax (NVAX) stock is 2.39 as of July 11, 2025.
Does Novavax stock pay dividends?
No, Novavax (NVAX) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Novavax dividend payment date?
Novavax (NVAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Novavax?
Novavax (NVAX) has a beta rating of 3.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.